Updated COMMANDS trial data show Reblozyl improved survival and long-term transfusion independence vs. Epogen in lower-risk MDS patients.
Guillermo Garcia-Manero, MD, MD Anderson Cancer Center
Advertisement
Articles by Guillermo Garcia-Manero, MD, MD Anderson Cancer Center
Advertisement
Latest Updated Articles
Luspatercept in the Treatment of Myelodysplastic SyndromesDecember 17th 2020
Work-up of Myelodysplastic SyndromesDecember 17th 2020
Treatment Goals in Myelodysplastic SyndromesDecember 17th 2020
Risk Assessment & Genetic Testing in Myelodysplastic SyndromesDecember 17th 2020
NGS in Myelodysplastic SyndromesDecember 17th 2020
Treatment Approach in Myelodysplastic SyndromesDecember 17th 2020
Advertisement
Advertisement
Trending on CURE
1
Clock Touches: An Advanced Balance Exercise for Patients with Cancer
2
Wildfire Smoke and Cancer Risk: What Patients Should Know
3
Family History of Cancer Fuels Oncology Nurse's Passion for Patient Care
4
Balance Exercises for Patients With Cancer: How the Single-Leg Stand Builds Stability
5